AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01401842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar ext. high intensity progressive resistance exercise
Description: 1 active set of 1 exercise, 1x/week, 11 weeks
Study NCT01401842 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity core stabilization exercise
Description: 1 set of 5 exercises, 1x/week, 11 weeks
Study NCT04248309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intramuscular progesterone 20-40mg from D3 until pregnancy test
Description: serum progesterone \<7.24ug/L, followed by randomized A1: plus additional treatment（intramuscular progesterone 20-40mg from D3 ）
Study NCT02000076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation allowing 3 h sleep at night
Description: Participants sleep at home while monitored with ambulatory polysomnography. For the full sleep condition, they are instructed to go to bed and to get up at the usual times that they would normally do that. For the sleep deprivation condition, they are instructed to go to bed 3 hours before the time when they would usually get up, and then to get up at that time.
Study NCT02000076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full sleep
Description: Participants sleep at home while monitored with ambulatory polysomnography. For the full sleep condition, they are instructed to go to bed and to get up at the usual times that they would normally do that. For the sleep deprivation condition, they are instructed to go to bed 3 hours before the time when they would usually get up, and then to get up at that time.
Study NCT03592966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wild Blueberry Powder
Description: Freeze-dried whole fruit blueberry drink.
Study NCT03592966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Freeze-dried placebo powder
Study NCT03372928 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard EAA
Description: EAA provided relative to body mass at a standard dose (0.10 g/kg) during energy deprivation
Study NCT03372928 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High EAA
Description: EAA provided relative to body mass at a high dose (0.30 g/kg) during energy deprivation
Study NCT02589496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg every 3 weeks
Study NCT05065931 — intervention group
Intervention type: OTHER
Intervention: Auxiliary diagnostic system by AI-CDSS
Description: Helping clinicians to make diagnoses by using CDSS based-on AI
Study NCT04076254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumins
Description: albumin 5%
Study NCT04076254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluid
Description: Ringer Lactate
Study NCT04375787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Patients received 80 mg atorvastatin before elective coronary angiography
Study NCT04375787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Patients received 80 mg atorvastatin before elective coronary angiography
Study NCT01383980 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Continuous Tube Feedings
Description: Tube feeds continued up until elective surgery.
Study NCT03289949 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Psilocybine
Description: Oral dose of psilocybine.
Study NCT03289949 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ketanserin
Description: Oral dose of ketanserin.
Study NCT02413840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baduanjin qigong
Study NCT03311321 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K2 (menaquinone-7; 360-mcg/d)
Description: four 90-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
Study NCT03311321 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Control
Description: four placebo softgel capsules per day for 8 weeks containing no vitamin K2 (menaquinone-7)
Study NCT04540549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: Jogging or cycling ≥5 days/week, 30-60 min/d
Study NCT01932242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETI-204
Description: Monoclonal Antibody
Study NCT01932242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for ETI-204
Study NCT04063241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Literacy-Informed Discharge Instructions
Description: Web-based disease-specific instruction sheets that will be printed with the research team's help. Providers will reference these instructions as they perform discharge counseling and will give parents a copy of the instructions to refer to at home.
Study NCT04063241 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Provider Training
Description: 20-minute long provider training session, including information about health literacy, advanced counseling strategies, results of prior studies, and pre-implementation data.
Study NCT03329196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-6548
Description: Oral tablet
Study NCT03329196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Subcutaneous
Study NCT01992120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Debriefing of high-fidelity sepsis simulation scenarios
Description: Educational intervention
Study NCT01992120 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Debriefing of high-fidelity non-sepsis simulation scenarios
Study NCT02525393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Stroke rehabilitation performed with the aid of a transcranial electrical stimulation device.
Study NCT02525393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Stroke rehabilitation performed with the aid of a repetitive transcranial magnetic stimulation device.
Study NCT02525393 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Stroke sham stimulation performed with the aid of a transcranial electrical stimulation device.
Study NCT02476825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Flixotide Accuhaler 500 micrograms b.i.d.
Study NCT02476825 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accuhaler
Description: Flixotide Accuhaler 500 micrograms b.i.d.
Study NCT03629236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GrafixPL
Description: Debridement, GrafixPL application, dressing application, standard compression therapy
Study NCT03629236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Debridement, dressing application, standard compression therapy
Study NCT01098981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial ultrasound as an adjunctive therapy to tPA
Description: * tPA per approved labeling administered over 60 minutes~* Ultrasonic headframe with active insonation for 120 minutes
Study NCT01098981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care tPA therapy for acute ischemic stroke
Description: * tPA per approved labeling administered over 60 minutes~* Ultrasonic headframe with sham (inactive) insonation for 120 minutes
Study NCT03085979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Burch Colposuspension
Description: Anti-incontinent surgery
Study NCT03085979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trans obturator tape
Description: Anti-incontinent surgery
Study NCT03085979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tension free vaginal tape
Description: Anti-incontinent surgery
Study NCT00830245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150mg/day
Study NCT03882138 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open flap debridement
Description: Modified Widman flap surgery followed by meticulous debridement, root planning and thorough irrigation with normal sterile saline solution
Study NCT00449670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)
Description: Two doses of the GSK1562902A adjuvanted split virus vaccine, administered intramuscularly into the deltoid region of the non-dominant arm at Day 0 and Day 21.
Study NCT00449670 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H5N1 non-adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)
Description: Two doses of the GSK1562902A non-adjuvanted split virus vaccine, administered intramuscularly into the deltoid region of the non-dominant arm at Day 0 and Day 21.
Study NCT00449670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 adjuvanted split virus vaccine (A/Indonesia/05/2005 strain)
Description: Booster administration at Month 6 (and a second booster dose 21 days later for the un-adjuvanted group only) with an adjuvanted split virus pandemic influenza candidate vaccine containing the strain A/Indonesia/5/2005.
Study NCT00449670 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H5N1 adjuvanted split virus vaccine (A/Indonesia/05/2005 strain)
Description: Booster administration at Month 6 (and a second booster dose 21 days later for the un-adjuvanted group only) with an adjuvanted split virus pandemic influenza candidate vaccine containing the strain A/Indonesia/5/2005.
Study NCT00613444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LumaCare LC-122M non-coherent light source
Description: Subjects will receive a series of up to 6 treatment sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, light treatment parameters will be within the guidelines normally used clinically for red-light non-coherrent light sources, and thus fluences used will not exceed 75 J/cm2.
Study NCT02596243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GX-188E
Description: 1mg of GX-188E administered IM using EP device at day 0, week 4 and week 12.
Study NCT02596243 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5mL of Placebo administered IM using EP device at day 0, week 4 and week 12.
Study NCT02460705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biologically active human fecal material, OpenBiome
Description: Fecal microbiota transplant
Study NCT01526044 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Freestyle Navigator
Description: Continuous glucose monitoring by subcutaneous measurement in the interstitial fluid
Study NCT01526044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freestyle Navigator
Description: Continuous glucose monitoring by subcutaneous measurement in the interstitial fluid
Study NCT02530372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UriCap-F
Description: non-invasive urine collection device for women
Study NCT03868852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib mesylate tablets
Description: Apatinib mesylate tablets were orally administered 250 mg QD from 1 week before radiotherapy to the whole radiotherapy period. (Appatinib is no longer used after radiotherapy)
Study NCT03868852 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Three-dimensional conformal intensity modulation
Description: Three-dimensional conformal intensity modulation (IMRT) technique was used for post-operative radiotherapy. The radiation dose was 45-54 Gy.
Study NCT01873417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012 (DMF)
Study NCT01971502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 1060469
Description: single rising doses
Study NCT01971502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469
Description: food effect
Study NCT01971502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469
Description: single rising doses
Study NCT03569046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthetic injection
Description: ear block by 0.25% bupivacaine
Study NCT03569046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Flush, 0.9% Injectable Solution
Description: ear block by Normal Saline Flush, 0.9% Injectable Solution
Study NCT03569046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: general anesthetic
Description: general anesthetic by midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 μg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air.
Study NCT03569046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: general anesthetic
Description: general anesthetic by midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 μg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air.
Study NCT03569046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hypotensives
Description: hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol
Study NCT03569046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypotensives
Description: hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol
Study NCT01129050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Fish oil capsule
Study NCT01129050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed Oil
Description: Flaxseed oil capsule
Study NCT01129050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soybean oil capsule
Study NCT01168973 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: 10 milligrams per kilogram (mg/kg) administered intravenously (IV) on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
Study NCT01168973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Ramucirumab)
Description: Administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
Study NCT01168973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: 75 milligrams per square meter (mg/m\^2) (60 mg/m\^2 for the countries of Korea and Taiwan only with protocol amendment dated 22 May 2012) administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
Study NCT01168973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 milligrams per square meter (mg/m\^2) (60 mg/m\^2 for the countries of Korea and Taiwan only with protocol amendment dated 22 May 2012) administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
Study NCT01410682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0,12% digluconate chlorhexidine
Description: Oral care with 0.12% Chlorhexidine Digluconate and toothbrushing is realized twice a day and took about 10 minutes to complete, depending on the child's acceptance and clinical conditions.
Study NCT01410682 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: toothbrushing
Description: Gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posterior to anterior movements.
Study NCT02767323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: excitatory 5Hz rTMS will be used
Study NCT02767323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham rTMS
Description: an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
Study NCT01865526 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Six point diet
Description: The 6-point diet is a list of six items indicating how to modify their dietary habits:~1. Do not add salt at table and for cooking;~2. Food to avoid: any kind of salami, sausages, cheese and dairy products or canned food;~3. Replace noodle or bread with special no-protein food;~4. The second course (meat, fish and eggs) are allowed once a day in the usual quantity;~5. 4-5 servings/day of fruits or vegetables are suggested;~6. Once or twice a week the main course may be of normal noodle with legumes instead of the second course, with fruit and vegetables.
Study NCT01865526 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low protein diet
Description: Classical low-protein diet prescribed according to the patients' desired body weight (DBW), obtained by multiplying the squared value of the height times a reference BMI value of 23. These diets contained at least 30 kcal/kg/day (25 in overweight patients), with a dietary sodium intake restricted to 2.5 g/day.
Study NCT01473342 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mila Blooms
Description: Behavioral intervention will be administered to 30 adolescent childhood cancer survivors \& their parents (3 blocks of 10 survivor-parent(s) groups) who serve as their own controls. The intervention phase begins at Week 9 (immediately following the 8-week control phase) and runs for 9 weeks (Weeks 9 - 17). Adolescents are assigned a smartphone installed with the Mila Blooms app to use for the first 8 weeks (Weeks 9 - 16) of the intervention. The app integrates (1) tools for tracking health behaviors (e.g., diet, physical activity, etc.); (2) an avatar system to provide virtual rewards, and (3) a social network of users for support. As part of the intervention, adolescents will also receive weekly coaching phone calls from study staff to discuss areas of concern and to encourage goal-setting \& participation. During the 9th week (Week 17), participants complete one final survey \& accelerometer wear.
Study NCT06021899 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: modified constraint induced movement therapy
Description: Modified CIMT protocol that was based on suggestions made by Dromerick, Edwards, and Hahn (2000) . Modifications were reductions in the duration of mitt wear and massed practice compared with the traditional protocol
Study NCT06021899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modified constraint induced movement therapy
Description: Modified CIMT protocol that was based on suggestions made by Dromerick, Edwards, and Hahn (2000) . Modifications were reductions in the duration of mitt wear and massed practice compared with the traditional protocol
Study NCT02809014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dentifrice F-Complex
Description: Use of few of dentifrice on brushing for one week, twice day.
Study NCT02809014 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dentifrice F-Complex
Description: Use of few of dentifrice on brushing for one week, twice day.
Study NCT02779946 — intervention group
Intervention type: DEVICE
Intervention: Fibro Scan
Study NCT02779946 — intervention group
Intervention type: GENETIC
Intervention: PNPLA3
Study NCT02809014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dentifrice F-Complex + NaF
Description: Use of few of dentifrice on brushing for one week, twice day.
Study NCT02809014 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dentifrice F-Complex + NaF
Description: Use of few of dentifrice on brushing for one week, twice day.
Study NCT02809014 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dentifrice standard
Description: Use of few of dentifrice on brushing for one week, twice day. It's for the positive control of fluoride
Study NCT02809014 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dentifrice standard
Description: Use of few of dentifrice on brushing for one week, twice day. It's for the positive control of fluoride
Study NCT02809014 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dentifrice with tara gum
Description: Use of few of dentifrice on brushing for one week, twice day. It's for analysis of negative control of fluoride and action only of tara gum.
Study NCT02146742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1707
Description: oral
Study NCT02146742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral
Study NCT01821833 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid
Description: Patients receive omega-3 fatty acid capsules orally beginning 1 week prior to paclitaxel treatment.~Capsule administration continues until paclitaxel is discontinued or for 12 weeks maximum (whichever comes first).~Each 1-gram capsule contains approximately 465 mg eicosapentaenoic acid (EPA) and 375 mg docosahexaenoic acid (DHA).
Study NCT01821833 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive placebo capsules orally beginning 1 week prior to paclitaxel treatment.~Capsule administration continues until paclitaxel is discontinued or for 12 weeks maximum (whichever comes first)